CH EPL (R5)
1.0.0-ballot - ballot
This page is part of the CH EPL (R5) (v1.0.0-ballot: DSTU 1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. This is the current published version. For a full list of available versions, see the Directory of published versions
Generated Narrative: RegulatedAuthorization FOPH-21529
CH - EPL Reimbursement SL
- FOPHDossierNumber: FOPH Dossier Number/21529
- status: Reimbursed
- statusDate: 2023-12-01
- expiryDate: 2026-03-31
- listingStatus: Listed
- listingPeriod: 2023-12-01 --> 2025-12-31
- firstListingDate: 2023-12-01
- costShare: 10
- gamme: Oral
CH - EPL Product Price
- value: CHF958.62 (CHF)
- type: Ex-factory price
- changeType: Price mutation after triennal review of pharmaceuticals
- changeDate: 2023-12-01
CH - EPL Product Price
- value: CHF1,113.95 (CHF)
- type: Retail price
- changeType: VAT-change
- changeDate: 2024-01-01
type: Reimbursement SL
| Extension | Reference |
| ClinicalUseDefinition: type = indication |
holder: Organization Pfizer AG
Generated Narrative: Organization #holder-Pfizer-AG
Profile: CH EPL Organization
identifier: LOC Identifier/100015286, GLN Identifier/7601001010604
name: Pfizer AG